Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.34 |
| ▸ | EGFR | P00533 | 1/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.33 |
| ▸ | RAPGEF3 | O95398 | 2/20 | 0.32 |
| ▸ | RET | P07949 | 1/20 | 0.32 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.32 |
| ▸ | HPGD | P15428 | 1/20 | 0.31 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.31 |
| ▸ | GRM2 | Q14416 | 2/20 | 0.31 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.30 |
| ▸ | SCD | O00767 | 1/20 | 0.30 |
| ▸ | SCD5 | Q86SK9 | 1/20 | 0.30 |
| ▸ | LMNA | P02545 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3809947 | 0.82 | EGFR (0.36) | SMN1; SMN2EGFRALDH1A1MAPK1RET | |
| SCHEMBL2677759 | 0.82 | EGFR (0.36) | SMN1; SMN2EGFRALDH1A1MAPK1RAPGEF3 | |
| SCHEMBL24939143 | 0.82 | SMN1; SMN2 (0.38) | SMN1; SMN2EGFRALDH1A1MAPK1RAPGEF3 | |
| SCHEMBL3709322 | 0.78 | SIRT6 (0.36) | SMN1; SMN2EGFRALDH1A1MAPK1RET | |
| SCHEMBL12467195 | 0.78 | KMT2A (0.42) | SMN1; SMN2ALDH1A1MAPK1RAPGEF3RET | |
| SCHEMBL1515627 | 0.78 | ALDH1A1 (0.49) | SMN1; SMN2EGFRALDH1A1MAPK1RAPGEF3 | |
| SCHEMBL11966189 | 0.77 | — | — | |
| Hydrochloric Acid SCHEMBL3712256 | 0.76 | ALDH1A1 (0.48) | SMN1; SMN2EGFRALDH1A1MAPK1RAPGEF3 | |
| SCHEMBL5376092 | 0.72 | HCRTR2 (0.35) | SMN1; SMN2EGFRALDH1A1MAPK1RET | |
| SCHEMBL19980443 | 0.69 | KMT2A (0.38) | ALDH1A1KMT2AGRM2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2376478-B1 | PYRIDYLOXYINDOLES INHIBITORS OF VEGF-R2 AND USE THEREOF FOR TREATMENT OF DISEASE | NOVARTIS AG (CH) | 2017-04-19 | — | — | EP | disclosed |
| US-8486954-B2 | Heterobicyclic carboxamides as inhibitors for kinases | NOVARTIS AG (CH) | 2013-07-16 | — | — | US | disclosed |
| US-20130005751-A1 | HETEROBICYCLIC CARBOXAMIDES AS INHIBITORS FOR KINASES | NOVARTIS AG (CH) | 2013-01-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130005751-A1 | HETEROBICYCLIC CARBOXAMIDES AS INHIBITORS FOR KINASES | CDK2, PHKG1, PHKG2 | SMN1; SMN2 4751/4885EGFR 180/4885ALDH1A1 3736/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.